Solara Active Pharma Sciences Limited (SOLARA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Solara Active Pharma Sciences Limited (SOLARA) has a cash flow conversion efficiency ratio of 0.059x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs740.70 Million ≈ $8.01 Million USD) by net assets (Rs12.57 Billion ≈ $135.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Solara Active Pharma Sciences Limited for the company's overall valuation and market capitalisation.
Solara Active Pharma Sciences Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Solara Active Pharma Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Solara Active Pharma Sciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solara Active Pharma Sciences Limited ranked by their cash flow conversion efficiency. Explore how high is Solara Active Pharma Sciences Limited's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinopower Semiconductor
TWO:6435
|
0.079x |
|
Jiangsu Jingxue Insulation
SHE:301010
|
0.044x |
|
Caregen Co.Ltd
KQ:214370
|
0.019x |
|
Text S.A.
WAR:TXT
|
0.303x |
|
Titan Acquisition Corp
NASDAQ:TACH
|
0.000x |
|
Laser Tek Taiwan Co Ltd
TWO:6207
|
0.037x |
|
AVCON Information Tech
SHE:300074
|
0.014x |
|
Hylink Digital Solution Co Ltd
SHG:603825
|
0.560x |
Annual Cash Flow Conversion Efficiency for Solara Active Pharma Sciences Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Solara Active Pharma Sciences Limited from 2017 to 2025. View today's stock price for Solara Active Pharma Sciences Limited for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs10.97 Billion ≈ $118.63 Million |
Rs2.13 Billion ≈ $23.02 Million |
0.194x | +66.91% |
| 2024-03-31 | Rs9.37 Billion ≈ $101.29 Million |
Rs1.09 Billion ≈ $11.77 Million |
0.116x | +11.78% |
| 2023-03-31 | Rs15.02 Billion ≈ $162.49 Million |
Rs1.56 Billion ≈ $16.90 Million |
0.104x | +165.95% |
| 2022-03-31 | Rs15.35 Billion ≈ $165.98 Million |
Rs-2.42 Billion ≈ $-26.17 Million |
-0.158x | -261.57% |
| 2021-03-31 | Rs15.93 Billion ≈ $172.25 Million |
Rs1.55 Billion ≈ $16.81 Million |
0.098x | -56.43% |
| 2020-03-31 | Rs10.90 Billion ≈ $117.90 Million |
Rs2.44 Billion ≈ $26.41 Million |
0.224x | +34.55% |
| 2019-03-31 | Rs9.60 Billion ≈ $103.85 Million |
Rs1.60 Billion ≈ $17.29 Million |
0.166x | +159.91% |
| 2018-03-31 | Rs7.68 Billion ≈ $83.11 Million |
Rs492.23 Million ≈ $5.32 Million |
0.064x | -100.00% |
| 2017-03-31 | Rs67.00K ≈ $724.58 |
Rs492.23 Million ≈ $5.32 Million |
7346.716x | -- |
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more